中东和非洲肺动脉高压市场预测至 2028 年 - COVID-19 影响和区域分析 - 按药物 [内皮素受体拮抗剂 (ERA)、前列环素和前列环素类似物、sGC 刺激剂和 pde-5 试纸],类型(品牌药和仿制药)、给药途径(口服、静脉/皮下和吸入)和分销渠道(医院药房和诊所、网上药房和零售药房)

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2028


No. of Pages: 134    |    Report Code: BMIRE00028069    |    Category: Life Sciences

Middle East & Africa Pulmonary Arterial Hypertension Market

中东和中东地区非洲肺动脉高压市场预计将从2022年的4.1088亿美元增长到2028年的5.3574亿美元;预计 2022 年至 2028 年复合年增长率为 4.5%。

 

专利到期时间增长至为中东和中东地区提供丰厚的机会预测期内非洲肺动脉高压市场的增长

 

专利到期允许仿制药进入市场并使产品供应多样化。预计一些专利产品将在未来几年失去专利,这可能为仿制药公司提供巨大的机会。许多制药公司(例如 Find Care Ratings)已经在致力于开发专利产品的仿制药。专利到期后,可以使用仿制药。虽然消费者从低价中受益,但失去专利保护可能会使制药公司面临日益激烈的竞争。因此,专利到期预计将为仿制药制造商提供进入新市场的机会。因此,不断增长的专利到期预计将为中东和中东地区提供利润丰厚的机会。非洲肺动脉高压市场未来几年将增长。

 

中东和非洲非洲肺动脉高压市场概况

 

中东和非洲非洲肺动脉高压市场分为阿联酋、沙特阿拉伯、南非以及中东和非洲其他地区。非洲。预计沙特阿拉伯将在预测期内(即 2022 年至 2028 年)占据最大的市场份额。预计沙特阿拉伯的肺动脉高压市场将出现可观的增长。沙特阿拉伯是中东最大的经济体,在全国各种研发项目的发展方面表现出色。该国在药品制造领域正在变得知名。此外,沙特阿拉伯预计将对中东和中东地区产生积极影响。由于各种法规以及该国对肺动脉高压药物的高需求,非洲肺动脉高压市场。此外,一些组织正在提高沙特阿拉伯民众对多环芳烃的认识和了解。例如,沙特肺动脉高压协会 (SAPH) 正在努力提高沙特阿拉伯医疗专业人员对肺血管疾病的认识和知识。此外,沙特阿拉伯政府启动了“沙特愿景2030”计划,以减少石油依赖并使包括医疗保健在内的其他行业多元化,这导致医疗保健服务取得重大发展,并提高先进医疗技术的采用率。根据“2030 年愿景”,沙特阿拉伯政府计划投资超过 650 亿美元,通过优先考虑本地药品和医疗器械生产来发展该国的医疗保健基础设施。因此,人们对 PAH 的认识不断提高以及沙特 2030 年愿景的推出预计将推动中东和中东地区的增长。未来几年沙特阿拉伯的非洲肺动脉高压市场。

 

中东和非洲非洲肺动脉高压市场收入及预测至 2028 年(十亿美元)

中东和非洲非洲肺动脉高压市场细分

 

中东和非洲非洲肺动脉高压市场根据药物、类型、给药途径、分销渠道和国家进行细分。

 

基于毒品、中东和非洲肺动脉高压市场分为内皮素受体拮抗剂 (ERA)、前列环素和前列环素类似物、sGC 刺激剂和 pde-5 试纸。 2022 年,前列环素和前列环素类似物细分市场在中东和非洲地区占据最大份额。非洲肺动脉高压市场。

 

根据类型,中东和非洲肺动脉高压市场。非洲肺动脉高压市场分为品牌药和仿制药。 2022 年,品牌细分市场在中东和非洲地区占据更大份额。非洲肺动脉高压市场。

 

根据给药途径,中东和非洲肺动脉高压市场。非洲肺动脉高压市场分为口服、静脉/皮下和吸入。 2022 年,口腔细分市场在中东和非洲地区占据最大份额。非洲肺动脉高压市场。

 

根据分销渠道,中东和非洲肺动脉高压市场。非洲肺动脉高压市场分为医院药房和诊所、在线药房和零售药房。 2022 年,医院药房和诊所部门在中东和非洲地区占据最大份额。非洲肺动脉高压市场。

 

基于国家、中东和非洲地区。非洲肺动脉高压市场分为沙特阿拉伯、南非、阿联酋以及中东其他地区和地区。非洲。 2022年,沙特阿拉伯在中东和非洲地区的份额最大。非洲肺动脉高压市场。

 

拜耳公司、吉利德科学公司、葛兰素史克公司、强生公司。 Johnson、Lupin Ltd、Novartis AG、Pfizer Inc 和 Teva Pharmaceutical Industries Ltd 是在中东和中东地区运营的领先公司。非洲肺动脉高压市场。



Middle East & Africa Pulmonary Arterial Hypertension Strategic Insights

Strategic insights for Middle East & Africa Pulmonary Arterial Hypertension involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/middle-east-and-africa-pulmonary-arterial-hypertension-market-strategic-framework.webp
Get more information on this report

Middle East & Africa Pulmonary Arterial Hypertension Report Scope

Report Attribute Details
Market size in 2022 US$ 410.88 Million
Market Size by 2028 US$ 535.74 Million
Global CAGR (2022 - 2028) 4.5%
Historical Data 2020-2021
Forecast period 2023-2028
Segments Covered By 药物
  • 内皮素受体拮抗剂
  • 前列环素和前列环素类似物
  • sGC 刺激剂
  • pde-5 试纸
By 类型
  • 品牌和通用
By 给药途径
  • 口服
  • 静脉/皮下
  • 吸入
By 分销渠道
  • 医院药房和诊所
  • 网上药房
  • 零售药房
Regions and Countries Covered 中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
Market leaders and key company profiles
  • Bayer AG
  • Gilead Sciences Inc
  • GSK Plc
  • Johnson & Johnson
  • Lupin Ltd
  • Novartis AG
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
  • Get more information on this report

    Middle East & Africa Pulmonary Arterial Hypertension Regional Insights

    The regional scope of Middle East & Africa Pulmonary Arterial Hypertension refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/middle-east-and-africa-pulmonary-arterial-hypertension-market-geography.webp
    Get more information on this report

    The List of Companies - Middle East & Africa Pulmonary Arterial Hypertension Market

    1. Bayer AG
    2. Gilead Sciences Inc
    3. GSK Plc
    4. Johnson & Johnson
    5. Lupin Ltd
    6. Novartis AG
    7. Pfizer Inc
    8. Teva Pharmaceutical Industries Ltd
    Frequently Asked Questions
    How big is the Middle East & Africa Pulmonary Arterial Hypertension Market?

    The Middle East & Africa Pulmonary Arterial Hypertension Market is valued at US$ 410.88 Million in 2022, it is projected to reach US$ 535.74 Million by 2028.

    What is the CAGR for Middle East & Africa Pulmonary Arterial Hypertension Market by (2022 - 2028)?

    As per our report Middle East & Africa Pulmonary Arterial Hypertension Market, the market size is valued at US$ 410.88 Million in 2022, projecting it to reach US$ 535.74 Million by 2028. This translates to a CAGR of approximately 4.5% during the forecast period.

    What segments are covered in this report?

    The Middle East & Africa Pulmonary Arterial Hypertension Market report typically cover these key segments-

  • 药物 (内皮素受体拮抗剂, 前列环素和前列环素类似物, sGC 刺激剂, pde-5 试纸)
  • 类型 (品牌和通用)
  • 给药途径 (口服, 静脉/皮下, 吸入)
  • What is the historic period, base year, and forecast period taken for Middle East & Africa Pulmonary Arterial Hypertension Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Pulmonary Arterial Hypertension Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2028
  • Who are the major players in Middle East & Africa Pulmonary Arterial Hypertension Market?

    The Middle East & Africa Pulmonary Arterial Hypertension Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Bayer AG
  • Gilead Sciences Inc
  • GSK Plc
  • Johnson & Johnson
  • Lupin Ltd
  • Novartis AG
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
  • Who should buy this report?

    The Middle East & Africa Pulmonary Arterial Hypertension Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Middle East & Africa Pulmonary Arterial Hypertension Market value chain can benefit from the information contained in a comprehensive market report.